Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics

GENEVA, SWITZERLAND / ACCESS Newswire / December 15, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics or the Company) announced today the completion of its business combination with NeuroX Group SA (NeuroX), a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases. The newly combined entity now operates under the name MindMaze Therapeutics Holding SA.

Foto: Accesswire

The closing follows the signing of a definitive business combination agreement in October 2025 and subsequent shareholder approval at the Company's extraordinary general meeting in November. The transaction establishes a fully integrated company with a first-of-its-kind ecosystem, uniting precision digital neurotherapeutics, pharmacological treatments, cutting-edge devices, data, and an AI-powered platform, positioned to redefine neurological care and change patient lives.

"Neurological diseases are one of the leading causes of disability globally," said Olaf Blanke (MD), member of the Board of Directors, Professor of Neuroscience and Cognitive Neuroprosthetics at the Swiss Federal Institute of Technology (EPFL) and Adjunct Professor at the Department of Clinical Neurosciences at the University Hospital of Geneva. "The situation is worsening due to aging populations, with 1 in 6 people expected to develop a neurological disease, making the need for effective, scalable solutions more urgent than ever. While neuro-rehabilitation requires intensive, repetitive training for functional recovery, traditional healthcare systems often fail to deliver adequate therapy, leaving millions of patients without optimal treatment. MindMaze Therapeutics seeks to address this gap by providing clinically proven neurotherapeutics to support their recovery journey, from hospital to rehab center to their home."

"Today begins a new chapter for MindMaze Therapeutics," commented Walid Hanna, Chairman of the Board of Directors of MindMaze Therapeutics. "The company is founded on clinically validated innovation, and driven by a mission to transform neurological care, addressing a critical and persistent gap in motor and cognition restorations in neurological conditions. We are now focused on advancing our precision neurotherapeutics platform to deliver impact at scale. Relief's complementary capabilities and biopharmaceutical assets strengthen our growth strategy, supporting both drug-digital integration and expanding development opportunities."